Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Cholet Agglo Tour: Lukáš Kubiš wins from the breakaway in rain-soaked round of the Coupe de France

The Slovakian rider outsprints Benjamin Thomas and Niklas Larsen for the victory in Cholet

Cycling News

Trump and Putin teased ‘enormous economic deals’ in their call—but U.S. companies will experience a very different Russia if they return

Russia has a new business elite and radically altered marketplace—and it’s done away with key legal protections.

Fortune

Katy Perry Flaunts Her Weight Loss After Addressing Ozempic Rumors: “She Looks Worse”

"The Ozempic face is crazy and her fillers are terrible" The post Katy Perry Flaunts Her Weight Loss After Addressing Ozempic Rumors: “She Looks Worse” first appeared on Bored Panda.

Bored Panda

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Ozempic can cost almost $2,000 a year. An Australian peak medical body says it should be on the PBS for weight loss

Research shows weight loss-inducing semaglutide medicines can help lower the risk of cardiovascular conditions and sleep apnea

The Guardian - AU

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Barchart

“Horrible Side Effects”: Experts Warn About Hollywood’s Ozempic Obsession

"Prioritize mental health." Hollywood’s “Ozempic craze” is worrying experts who believe it may be promoting harmful beauty standards. The post “Horrible Side Effects”: Experts Warn About Hollywood’s Ozempic Obsession first appeared on Bored Panda.

Bored Panda

Read news from The Economist, FT, and more,
with one subscription

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Investors Business Daily

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

MarketBeat

Stock Market Today: Dow Jones Dives 890 Points On These Trump Recession Fears; Tesla Plummets As Elon Musk Reveals This Attack (Live Coverage)

The Dow Jones plunged on the stock market today after President Donald Trump spoke about recession and tariffs. Tesla and Palantir took a dive.

Investors Business Daily

Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Investors Business Daily

How to eat well with diabetes – and save money doing it

Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s created a collection of easy, affordable recipes designed for people with type 2 diabetes – meals that don’t just tick the nutritional boxes but taste good too, says…

The Independent UK

Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher

Weight loss drugs are already taking a bite out of many people’s wallets.

Fortune

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy

Novo Nordisk slashed the price of Wegovy by more than half on Wednesday amid a bitter rivalry with Hims & Hers Health.

The Independent UK

Weight-loss jab use rising among people with eating disorders, experts warn as NHS chief calls for crackdown

Online pharmacies and private providers have been urged to ‘act responsibly’ and ensure that the drugs are only prescribed to people with a medical need

Cycling Weekly

Class of 2025: Meet the 12 British cyclists who turned pro this year

A bounteous 12 Brits have stepped up to the pro ranks in 2025. Tom Davidson traces the skyward trajectories of a former runner, an adoptive Italian, and the WorldTour’s youngest rider

Investors Business Daily

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Investors Business Daily

Why IBD 50's Top Seed, Hims & Hers, Just Crashed On Its Upbeat Earnings

Hims stock plunged Tuesday after the compounding pharmacy issued a bullish outlook that still includes knockoff versions of semaglutide.

The Independent UK

Weight loss drugs linked to dozens of deaths

The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs

Investors Business Daily

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

MarketBeat

These 3 Stocks Just Announced Major Dividend Hikes

See which three stocks just raised their dividend payments by over 15%. On firm now has a sky-high indicated yield of over 10%.

MarketBeat

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

Evening Standard

Novo Nordisk reprimanded for allegedly failing to disclose payments

The manufacturer of the weight loss jab Wegovy said it ‘is dedicated to working transparently and ethically’.

1 2 3 4 5

People

Benjamin Thomas Cofidis

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.